Payment overview · 2025
General Payments
$1,356.08
63 reported records · 19 companies
Healthcare provider profile · identity verified
Fred A Nordquist, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PLEASANT VIEW, TN · NPI 1043294747
Verified facts
What the public records show
CMS Open Payments records show Fred A Nordquist, M.D. received $1,356.08 in general payments during 2025 across 63 reported records.
Novo Nordisk Inc accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Rybelsus, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $276.46 | 20.4% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $172.60 | 12.7% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $133.79 | 9.9% | 7 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $128.76 | 9.5% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $86.56 | 6.4% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $72.56 | 5.3% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $63.82 | 4.7% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $62.79 | 4.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.04 | 4.6% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $58.85 | 4.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.62 | 2.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.96 | 2.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $30.14 | 2.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $27.69 | 2.0% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $27.28 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.10 | 1.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.17 | 1.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.09 | 1.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.80 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,356.08 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $238.80 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $161.81 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $130.68 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $128.76 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $96.63 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $92.24 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $86.56 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $72.56 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $63.82 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $62.79 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.04 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $58.85 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $50.43 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $41.81 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.66 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.62 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.62 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $35.08 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $32.96 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $30.14 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $27.69 | 1 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $27.28 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 96 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 91 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 159 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 52 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 20 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
91 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
159 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 27 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 921 | 309 |
| Losartan Potassium | Losartan Potassium | 467 | 158 |
| Lisinopril | Lisinopril | 457 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 416 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 409 | 145 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 390 | 132 |
| Omeprazole | Omeprazole | 335 | 120 |
| Tamsulosin Hcl | Tamsulosin Hcl | 291 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 87 |
| Metformin Hcl Er | Metformin Hcl | 268 | 93 |
| Clopidogrel | Clopidogrel Bisulfate | 212 | 63 |
| Furosemide | Furosemide | 212 | 81 |
| Metformin Hcl | Metformin Hcl | 210 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 204 | 69 |
| Methylprednisolone | Methylprednisolone | 201 | 142 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 65 |
| Trazodone Hcl | Trazodone Hcl | 183 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 182 | 61 |
| Ezetimibe | Ezetimibe | 166 | 57 |
| Famotidine | Famotidine | 164 | 73 |
| Celecoxib | Celecoxib | 163 | 62 |
| Ozempic | Semaglutide | 159 | 43 |
| Simvastatin | Simvastatin | 153 | 51 |
| Pioglitazone Hcl | Pioglitazone Hcl | 152 | 53 |
| Glimepiride | Glimepiride | 147 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 55 |
| Allopurinol | Allopurinol | 122 | 43 |
| Potassium Chloride | Potassium Chloride | 115 | 43 |
| Donepezil Hcl | Donepezil Hcl | 112 | 35 |
| Sertraline Hcl | Sertraline Hcl | 112 | 42 |
| Carvedilol | Carvedilol | 108 | 39 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 106 | 40 |
| Gabapentin | Gabapentin | 105 | 39 |
| Azithromycin | Azithromycin | 102 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 102 | 36 |
| Eliquis | Apixaban | 96 | 27 |
| Baclofen | Baclofen | 94 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 93 | 45 |
| Farxiga | Dapagliflozin Propanediol | 91 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 36 |
| Jardiance | Empagliflozin | 81 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 31 |
| Atenolol | Atenolol | 76 | 26 |
| Finasteride | Finasteride | 75 | 27 |
| Pregabalin | Pregabalin | 75 | 23 |
| Fluconazole | Fluconazole | 73 | 39 |
| Montelukast Sodium | Montelukast Sodium | 68 | 27 |
| Chlorthalidone | Chlorthalidone | 67 | 28 |
| Meloxicam | Meloxicam | 66 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 24 |
| Mounjaro | Tirzepatide | 63 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 25 |
| Mirtazapine | Mirtazapine | 61 | 26 |
| Alendronate Sodium | Alendronate Sodium | 60 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 22 |
| Alprazolam | Alprazolam | 54 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 54 | 21 |
| Tramadol Hcl | Tramadol Hcl | 53 | 23 |
| Synthroid | Levothyroxine Sodium | 52 | 20 |
| Acyclovir | Acyclovir | 51 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 21 |
| Mupirocin | Mupirocin | 51 | 32 |
| Nifedipine Er | Nifedipine | 51 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 40 |
| Xarelto | Rivaroxaban | 50 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 32 |
| Buspirone Hcl | Buspirone Hcl | 46 | 21 |
| Meclizine Hcl | Meclizine Hcl | 46 | 25 |
| Valacyclovir | Valacyclovir Hcl | 46 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 37 |
| Glipizide Er | Glipizide | 45 | 17 |
| Spironolactone | Spironolactone | 45 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 44 | 18 |
| Glipizide | Glipizide | 39 | 11 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | 16 |
| Prednisone | Prednisone | 38 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 15 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 36 | 12 |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 11 |
| Lovastatin | Lovastatin | 34 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 34 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 15 |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Etodolac | Etodolac | 31 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | suppressed |
| Nystatin | Nystatin | 30 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | 14 |
| Ramipril | Ramipril | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 22 |
| Propranolol Hcl | Propranolol Hcl | 29 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 15 |
| Ondansetron Odt | Ondansetron | 22 | 14 |
| Amoxicillin | Amoxicillin | 21 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 17 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Epinephrine | Epinephrine | 17 | 17 |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,356.08 · 63 records | Novo Nordisk Inc | ACCRUFER, AIRSUPRA, AREXVY, CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, FABRAZYME, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, Kerendia, Korlym, LEQVIO, MOUNJARO, NEFFY, NURTEC ODT, Ozempic, PREVNAR 20, REXULTI, Rybelsus, SYNTHROID, TRELEGY ELLIPTA, TZIELD, UBRELVY, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error